CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (117)	11/11/2003 9:12:46 AM
From: rkrw	Read Replies (2) of 411

In March 1997, CVT entered into two research collaboration and license agreements, one with Biogen, Inc. ("Biogen") and one with Biogen's wholly-owned subsidiary, Biotech Manufacturing Ltd. ("Biotech Manufacturing"), pursuant to which CVT granted the Biogen entities exclusive worldwide rights to develop and commercialize CVT-124 (the "Biogen Agreements"). From CV's S1 9/25/1996!! Two of the Company's drug candidates, CVT-124 and ranolazine, are in clinical trials. CVT-124, an adenosine A(1) receptor antagonist discovered by CVT, has potential applications in the treatment of edema associated with congestive heart failure ("CHF") and in the prevention and treatment of acute renal failure. A Phase I/II study completed by the Company in the United States indicated that CVT-124 is generally well tolerated and produces diuretic activity in healthy volunteers. Approximately one-quarter of the 875,000 hospitalized CHF patients in the United States do not respond sufficiently to currently available diuretics. The Company believes that these patients would represent the initial target market for CVT-124 in this indication.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next